About Nafithromycin:
- It is an antibiotic which has been developed with the support of “Biotechnology Industry Research Assistance Council” (BIRAC).
- It has been brought to market under the trade name “Miqnaf”.
- It is the first molecule entirely conceptualized, developed and clinically validated in India.
- It is the country’s first indigenously developed antibiotic aimed at tackling Antimicrobial Resistance (AMR).
- It is effective against resistant respiratory infections, particularly useful for cancer patients and poorly controlled diabetics.
- This innovation is designed to treat Community-Acquired Bacterial Pneumonia (CABP).
- Nafithromycin’s efficacy stands out as it targets both typical and atypical pathogens, offering a potent solution where no new antibiotic in this class has been developed worldwide for over three decades.
What is Antimicrobial Resistance (AMR)?
- It occurs when bacteria, viruses, fungi and parasites no longer respond to antimicrobial medicines.
- As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become difficult or impossible to treat.
- It increases the risk of disease spread, severe illness, disability and death.
- AMR is a natural process driven by genetic changes in pathogens over time, its spread is significantly accelerated by human activities.
